Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02408965 · ClinicalTrials.gov registry record · Phase 4
Uterotonic Prophylaxis Trial
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 284
- Enrollment target
NCT02408965 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 284 participants.
The verdict
NCT02408965, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 284 participants
- Enrollment target
Study Summary
Excessive bleeding after dilation and evacuation (D\&E) requiring interventions is common, occurring in approximately 30% of cases at one large abortion-providing clinic. Uterotonic prophylaxis at the time of D\&E, particularly with methylergonovine maleate (MM), is a common practice among D\&E providers despite nearly no evidence for its efficacy. Finding ways to decrease excessive bleeding after D\&E has the potential both to improve patient safety and to reduce costs of provider-initiated interventions. The investigators propose a randomized, controlled trial to investigate the efficacy of MM prophylaxis versus placebo in decreasing excessive bleeding measured by a composite outcome among women undergoing D\&E at 20 to 24 weeks.
Interventions
- OTHER placebo
- DRUG Methergine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02408965
The ClinicalTrials.gov registry entry for NCT02408965 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02408965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02408965 about?
NCT02408965 is a clinical study titled "Uterotonic Prophylaxis Trial". Excessive bleeding after dilation and evacuation (D\&E) requiring interventions is common, occurring in approximately 30% of cases at one large abortion-providing clinic. Uterotonic prophylaxis at the time of D\&E, particularly with methylergonovine maleate (MM), is a common practice among D\&E prov...
What is the current status of trial NCT02408965?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 284 participants. The study started on 2015-03. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02408965?
The interventions under investigation include: placebo (OTHER), Methergine (DRUG).
Who is sponsoring clinical trial NCT02408965?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.